Literature DB >> 20444501

Naturally occurring glycan forms of human immunoglobulins G1 and G2.

Gregory C Flynn1, Xiaoyu Chen, Y Diana Liu, Bhavana Shah, Zhongqi Zhang.   

Abstract

High resolution glycan mapping was performed on human immunoglobulin G (IgG) obtained from individual healthy subjects and from a combined sample of healthy subjects. In addition to the commonly known complex glycans, a variety of minor glycans are described and quantified, including high mannose forms and several previously unreported hybrid forms. Fc specific glycan analysis was also performed through peptide mapping with LC/MS/MS. Differences in the glycan linked Fc peptide masses allowed glycan profiles to be analyzed and quantified from IgG1 and IgG2 simultaneously for each subject within the same sample. Glycan profiles differed between subtypes, with greater levels of more fully galactosylated species found on IgG1 (e.g. G2F, SG2F) than IgG2. These results also show that Gal attachment on G1F is biased to the Man (alpha1-->6) arm for IgG1 and on the Man (alpha1-->3) arm for IgG2 from individual healthy subjects. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444501     DOI: 10.1016/j.molimm.2010.04.006

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  38 in total

1.  N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies.

Authors:  Y Diana Liu; Andrew M Goetze; Randal B Bass; Gregory C Flynn
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

Review 2.  IgG Fc Glycosylation in Human Immunity.

Authors:  Taia T Wang
Journal:  Curr Top Microbiol Immunol       Date:  2019       Impact factor: 4.291

Review 3.  IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease.

Authors:  Jing Xue; Li-Ping Zhu; Qiang Wei
Journal:  Glycoconj J       Date:  2013-06-20       Impact factor: 2.916

Review 4.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

Review 5.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

Review 6.  Assessing monoclonal antibody product quality attribute criticality through clinical studies.

Authors:  Andrew M Goetze; Matthew R Schenauer; Gregory C Flynn
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

7.  Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry.

Authors:  Sara Rosati; Yang Yang; Arjan Barendregt; Albert J R Heck
Journal:  Nat Protoc       Date:  2014-03-27       Impact factor: 13.491

Review 8.  Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors:  Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

9.  Structural characterization of the Man5 glycoform of human IgG3 Fc.

Authors:  Ishan S Shah; Scott Lovell; Nurjahan Mehzabeen; Kevin P Battaile; Thomas J Tolbert
Journal:  Mol Immunol       Date:  2017-10-12       Impact factor: 4.407

10.  Impact of Glycosylation on the Local Backbone Flexibility of Well-Defined IgG1-Fc Glycoforms Using Hydrogen Exchange-Mass Spectrometry.

Authors:  Apurva S More; Ronald T Toth; Solomon Z Okbazghi; C Russell Middaugh; Sangeeta B Joshi; Thomas J Tolbert; David B Volkin; David D Weis
Journal:  J Pharm Sci       Date:  2018-05-08       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.